Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Atezolizumab + Nab-paclitaxel |
| Indication/Tumor Type | triple-receptor negative breast cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | triple-receptor negative breast cancer | sensitive | Atezolizumab + Nab-paclitaxel | Phase III | Actionable | In a Phase III trial (IMpassion130), Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) resulted in improved progression-free survival (7.5 vs 5.0 months, HR=0.62, p<0.001) and overall survival (25.0 vs 15.5 months, HR=0.62) compared to placebo in patients with CD274 (PD-L1)-positive (>1%), advanced triple-receptor negative breast cancer (PMID: 30345906; NCT02425891). | detail... 30345906 detail... |
| CD274 positive | triple-receptor negative breast cancer | sensitive | Atezolizumab + Nab-paclitaxel | Guideline | Actionable | The combination of Tecentriq (atezolizumab) and Abraxane (nab-paclitaxel) is included in guidelines as first line therapy for CD274 (PD-L1)-positive patients with triple-negative breast cancer (PMID: 34678411; ESMO.org). | 34678411 detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (30345906) | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. | Full reference... |
| ESMO Clinical Practice Guidelines | Full reference... | |
| Full reference... | ||
| Tecentriq (atezolizumab) FDA Drug Label | Full reference... | |
| (34678411) | ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. | Full reference... |